Bioequivalence study of generic gliclazide and Diamicron formulations in healthy Thai male volunteers

International Journal of Clinical Pharmacology and Therapeutics

Volumn 41, Issue 7, 2003, Pages 323-330

  Rojanasthien, N ^a   Sugunta, C ^a   Rungapinan, S ^a   Kumsorn, B ^a   Sangdee, C ^a  

^a Faculty of Medicine Chiang Mai University   (Thailand)

Author keywords

Bioequivalence; Diamicron; Gliclazide

Indexed keywords

GENERIC DRUG; GLICLAZIDE;

ADULT; ANALYSIS OF VARIANCE; AREA UNDER THE CURVE; ARTICLE; BIOEQUIVALENCE; BLOOD ANALYSIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIET RESTRICTION; DRUG BLOOD LEVEL; DRUG ELIMINATION; DRUG FORMULATION; DRUG HALF LIFE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN EXPERIMENT; MALE; NORMAL HUMAN; RANDOMIZED CONTROLLED TRIAL; THAILAND;

EID: 0038267641     PISSN: 09461965     EISSN: None     Source Type: Journal    
DOI: 10.5414/CPP41323     Document Type: Article

References (12)

1. Alberti KG 1994 Gliclazide: review of metabolic and vascular action. Diabetes Metab 20: 341-348
2. Campbell DB, Lavielle R, Nathan C 1991 The mode of action and clinical pharmacology of gliclazide: a review. Diab Res Clin Pract 14 (Suppl 2): S21-36
3. Crepaldi G, Fioretto P 2000 Gliclazide modified release: its place in the therapeutic armamentarium. Metabolism 49 (10 Suppl 2): 21-25
4. Diletti E, Hauschke D, Steinijans VW 1991 Sample size determination for bioequivalence assessment by means of confidence intervals. Int J Clin Pharmacol Ther Toxicol 29: 1-8
5. Forette B, Rolland A, Hopkins Y, Gordon B, Campbell B 1982 Gliclacide pharmacokinetics in the elderly. In: Alberti et al (eds.) 11th congress of the international diabetes federation. Excerpta Medica, Amsterdam. Abstracts 9.
6. Harrower A 2000 Gliclazide modified release: form once-daily administration to 24-hour blood glucose control. Metabolism 49 (10 Suppl 2): 7-11
7. Jennings PE 1994 From hemobiology to vascular disease: a review of the potential of gliclazide to influence the pathogenesis of diabetic vascular disease. J Diabetes Complications 8: 226-230
8. Nation LR, Sansom NL 1994 Bioequivalence requirements for generic products. Pharmacol Ther 62: 42-55
9. Noguchi H, Tomita N, Naruto S, Nakano S 1992 Determination of gliclazide in plasma by high-performance liquid chromatography using solid-phase extraction. J Chromatogr 538: 266-269
10. Palmer KJ, Brogden RN 1993 Gliclazide. An update of its pharmacological properties and therapeutic efficacy in non-insulin-dependent diabetes mellitus. Drugs 46: 92-125
11. Sauter R, Steinijans VW, Diletti E, Bohm A, Schultz HU 1992 Presentation of results from bioequivalence studies. Int J Clin Pharmacol Ther 30 (Suppl 1): S7-30
12. Schulz HU, Steinijans VW 1991 Striving for standards in bioequivalence assessment: a review. Int J Clin Pharmacol Ther Toxicol 29: 293-298